ChristianC.ApfelMD
Oncology • Redwood City, CAAdjunct Associate Professor, UCSF School of Medicine, San Francisco, and Founder & CEO, SageMedic Corp, Redwood City
Dr. Apfel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
555 Twin Dolphin Drive, Suite 110
Redwood City, CA 94065
Summary
- I am the Founder and CEO of SageMedic Corp., that has developed the next generation of precision oncology. This is accomplished through a functional profiling platform of fresh patient biopsies that can identify the most effective treatment independent of conventional biomarkers or genomic testing.
Education & Training
University of Giessen Faculty of MedicineClass of 1992
Certifications & Licensure
CA State Medical License 2009 - 2026
Clinical Trials
- Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV) Start of enrollment: 2007 Aug 01
- Monitoring Exhaled Propofol to Individualize General Anesthesia Start of enrollment: 2010 Aug 01
Publications & Presentations
PubMed
- 459 citationsFourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting.Tong J. Gan, Kumar G. Belani, Sergio D. Bergese, Frances Chung, Pierre Diemunsch
Anesthesia and Analgesia. 2020-08-01 - 31 citationsEffect of i.v. acetaminophen on total hip or knee replacement surgery: a case-matched evaluation of a national patient database.Christian C. Apfel, Jonathan R. Jahr, Colleen L. Kelly, Robert Y. Ang, Gary M. Oderda
American Journal of Health-System Pharmacy. 2015-11-15 - 11 citationsPredictors for postoperative nausea and vomiting after xenon-based anaesthesia.Maximilian S. Schaefer, Christian C. Apfel, H.-J. Sachs, R. Stuttmann, Berthold Bein
British Journal of Anaesthesia. 2015-07-01
Authored Content
- The SAGE Direct Test (TM): A reliable way of functional profiling to predict the most effective treatment for cancer patientsAugust 2020
- A functional precision medicine 3D microtumor platform to identify and personalize novel indicationsMay 2020
- PDX validation of a 3D microtumor platformJune 2019
- Chemosensitivity profile of HCT-116 colorectal cancer cells in 3D spheroids compared to 2D monolayersMay 2014
- Accuracy and clinical utility of in vitro cytometric profiling to personalize chemotherapy: Preliminary findings of a systematic review and meta-analysisMay 2013
- Join now to see all
Professional Memberships
- Member
- Society of Integrative OncologyMember
External Links
- LinkedInhttps://www.linkedin.com/in/chrisapfel/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
